Combretum mucronatum and Capparis thonningii prevent scopolamine-induced memory deficit in mice

Pharmaceutical Biology

Volumn 51, Issue 1, 2013, Pages 49-57

  Ishola, Ismail Ogunbayode ^a,b   Adeyemi, Olufunmilayo Olaide ^a   Agbaje, Esther Oluwatoyin ^a   Tota, Santoshkumar ^b   Shukla, Rakesh ^b  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Acetylcholinesterase; Dementia; Learning; Morris water maze; Oxidative stress; Passive avoidance

Indexed keywords

ACETYLCHOLINESTERASE; CAPPARIS THONNINGII EXTRACT; COMBRETUM MUCRONATUM EXTRACT; GLUTATHIONE; MALONALDEHYDE; NOOTROPIC AGENT; PLANT EXTRACT; TACRINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME ACTIVITY; LATENT PERIOD; LOCOMOTION; MAZE TEST; MOUSE; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PLANT ROOT; PROTEIN FUNCTION; ROTAROD TEST; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AVOIDANCE LEARNING; BRAIN; CAPPARIS; CHOLINESTERASE INHIBITORS; COMBRETUM; DEMENTIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MAZE LEARNING; MEDICINE, AFRICAN TRADITIONAL; MEMORY DISORDERS; MICE; NIGERIA; OXIDATIVE STRESS; PLANT EXTRACTS; PLANT ROOTS; SCOPOLAMINE HYDROBROMIDE; TACRINE;

CAPPARACEAE; CAPPARIS; COMBRETACEAE; COMBRETUM; MUS;

EID: 84871380647     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2012.704518     Document Type: Article

References (40)

1. Agrawal R, Tyagi E, Saxena G, Nath C. (2009). Cholinergic influence on memory stages: A study on scopolamine amnesic mice. Indian J Pharmacol, 41, 192-196
2. Ahmed T, Gilani AH. (2009). Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamineinduced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav, 91, 554-559
3. Ajaiyeoba EO, Sama W. (2006). Phytochemical and antimicrobial studies of C. thonningii and C. tormentosa. Pharmacog Mag, 2, 118-122
4. Bartus RT. (2000). On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol, 163, 495-529 (Pubitemid 30399100)
5. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science. 217, 408-414
6. Burkhill HM. (1985). The Useful Plants of West Tropical Africa, Vol.1 2nd edition. UK: White Friars Press
7. Dringen R, Gutterer JM, Hirrlinger J. (2000). Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem, 267, 4912-4916 (Pubitemid 30641287)
8. Ebert U, Kirch W. (1998). Scopolamine model of dementia: Electroencephalogram findings and cognitive performance. Eur J Clin Invest, 28, 944-949 (Pubitemid 28521587)
9. Ellman GL. (1959). Tissue sulfhydryl groups. Arch Biochem Biophys, 82, 70-77
10. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7, 88-95
11. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary Eel-D. (2003). Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. Pharmacol Biochem Behav, 76, 525-533 (Pubitemid 37487909)
12. Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M. (2005). Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett, 374, 222-226 (Pubitemid 40128300)
13. Francis PT, Palmer AM, Snape M, Wilcock GK. (1999). The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry, 66, 137-147 (Pubitemid 29103513)
14. Gilgun-Sherki Y, Melamed E, Offen D. (2002). Antioxidant treatment in Alzheimer's disease: Current state. J Mol Neurosci, 21, 1-11
15. Giovannini MG, Casamenti F, Bartolini L, Pepeu G. (1997). The brain cholinergic system as a target of cognition enhancers. Behav Brain Res, 83, 1-5 (Pubitemid 27086607)
16. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. (1982). Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem, 126, 131-138 (Pubitemid 13203451)
17. Harvsteen BH. (2002). The biochemistry and medical significance of the flavonoids. Pharmacol Ther, 96, 67-202
18. Hermans RH, Hunter DE, McGivern RF, Cain CD, Longo LD. (1992). Behavioral sequelae in young rats of acute intermittent antenatal hypoxia. Neurotoxicol Teratol, 14, 119-129
19. Jeong EJ, Lee KY, Kim SH, Sung SH, Kim YC. (2008). Cognitiveenhancing and antioxidant activities of iridoid glycosides from Scrophularia buergeriana in scopolamine-treated mice. Eur J Pharmacol, 588, 78-84
20. Ji HF, Zhang HY. (2006). Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. J Mol Struct, 767, 3-9
21. Jones RW, Wesnes KA, Kirby J. (1991). Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci, 640, 241-244
22. Kulkarni KS, Kasture SB, Mengi SA. (2010). Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats. Indian J Pharmacol, 42, 168-173
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 265-275
24. Marcus DL, Thomas C, Rodriquez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. (1998). Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol, 150, 40-44 (Pubitemid 28146421)
25. Morris R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods, 11, 47-60 (Pubitemid 14088970)
26. Pachauri SD, Tota S, Khandelwal K, Verma PR, Nath C, Hanif K, Shukla R, Saxena JK, Dwivedi AK. (2012) Protective effect of fruits of Morinda citrifolia L. on scopolamine induced memory impairment in mice: A behavioral, biochemical and cerebral blood flow study. J Ethnopharmacol, 139, 34-41
27. Richetti SK, Blank M, Capiotti KM, Piato AL, Bogo MR, Vianna MR, Bonan CD. (2011). Quercetin and rutin prevent scopolamineinduced memory impairment in zebrafish. Behav Brain Res, 217, 10-15
28. Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J. (1995). Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl), 122, 158-168 (Pubitemid 26019151)
29. Sharma D, Puri M, Tiwary AK, Singh N, Jaggi AS. (2010). Antiamnesic effect of stevioside in scopolamine-treated rats. Indian J Pharmacol, 42, 164-167
30. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. (2008). Challenges for research on polyphenols from foods in Alzheimer's disease: Bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem, 56, 4855-4873 (Pubitemid 352039080)
31. Taffe MA, Weed MR, Gold LH. (1999). Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res, 8, 203-212 (Pubitemid 29518307)
32. Terry AV Jr, Buccafusco JJ. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther, 306, 821-827 (Pubitemid 37025286)
33. Tota S, Kamat PK, Awasthi H, Singh N, Raghubir R, Nath C, Hanif K. (2009). Candesartan improves memory decline in mice: Involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res, 199, 235-240
34. Tota S, Nath C, Najmi AK, Shukla R, Hanif K. (2012). Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: Role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism. Behav Brain Res, 232, 66-76
35. Vafeiadou K, Vauzour D, Spencer JP. (2007). Neuroinflammation and its modulation by flavonoids. Endocr Metab Immune Disord Drug Targets, 7, 211-224 (Pubitemid 47496628)
36. Ward CP, Redd K, Williams BM, Caler JR, Luo Y, McCoy JG. (2002). Ginkgo biloba extract: Cognitive enhancer or antistress buffer. Pharmacol Biochem Behav, 72, 913-922 (Pubitemid 34621318)
37. Wang C, Smith RL. (1975). Lowry determination of protein in the presence of Triton X-100. Anal Biochem, 63, 414-417
38. Yamada K, Komori Y, Tanaka T, Senzaki K, Nikai T, Sugihara H, Kameyama T, Nabeshima T. (1999). Brain dysfunction associated with an induction of nitric oxide synthase following an intracerebral injection of lipopolysaccharide in rats. Neuroscience, 88, 281-294 (Pubitemid 28440409)
39. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County study. Arch Neurol, 61, 82-88 (Pubitemid 38067418)
40. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR. (1997). A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol, 121, 827-833 (Pubitemid 27260791)